Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | huCART19 |
Trade Name | |
Synonyms | huCTL019|CTL119|autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T cells |
Drug Descriptions |
huCART19 comprise autologous T-cells engineered to express a humanized chimeric antigen receptor (CAR) that targets CD19, as well as CD3zeta chain and 4-1BB, which may result in increased T-cell response against CD19-expressing tumor cells (NCI Drug Dictionary, PMID: 38615142). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C156271 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CART22-65s cells + huCART19 | CART22-65s cells huCART19 | 0 | 2 |
huCART19 | huCART19 | 0 | 5 |